GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art

Abstract

Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide b.i.d. first approved to treat type 2 diabetes in 2005 have been further developed to yield effective compounds/preparations that have overcome the original problem of rapid elimination (short half-life), initially necessitating short intervals between injections (twice daily for exenatide b.i.d.). Scope of review To summarize current knowledge about GLP-1 receptor agonist. Major conclusions At present, GLP-1 RAs are injected twice daily (exenatide b.i.d.), once daily (lixisenatide and liraglutide), or once weekly (exenatide once weekly, dulaglutide, albiglutide, and semaglutide). A daily oral preparation of semaglutide, which has demonstrated clinical effectiveness close to the once-weekly subcutaneous preparation, was recently approved. All GLP-1 RAs share common mechanisms of action: augmentation of hyperglycemia-induced insulin secretion, suppression of glucagon secretion at hyper- or euglycemia, deceleration of gastric emptying preventing large post-meal glycemic increments, and a reduction in calorie intake and body weight. Short-acting agents (exenatide b.i.d., lixisenatide) have reduced effectiveness on overnight and fasting plasma glucose, but maintain their effect on gastric emptying during long-term treatment. Long-acting GLP-1 RAs (liraglutide, once-weekly exenatide, dulaglutide, albiglutide, and semaglutide) have more profound effects on overnight and fasting plasma glucose and HbA 1c , both on a background of oral glucose-lowering agents and in combination with basal insulin. Effects on gastric emptying decrease over time (tachyphylaxis). Given a similar, if not superior, effectiveness for HbA 1c reduction with additional weight reduction and no intrinsic risk of hypoglycemic episodes, GLP-1RAs are recommended as the preferred first injectable glucose-lowering therapy for type 2 diabetes, even before insulin treatment. However, GLP-1 RAs can be combined with (basal) insulin in either free- or fixed-dose preparations. More recently developed agents, in particular semaglutide, are characterized by greater efficacy with respect to lowering plasma glucose as well as body weight. Since 2016, several cardiovascular (CV) outcome studies have shown that GLP-1 RAs can effectively prevent CV events such as acute myocardial infarction or stroke and associated mortality. Therefore, guidelines particularly recommend treatment with GLP-1 RAs in patients with pre-existing atherosclerotic vascular disease (for example, previous CV events). The evidence of similar effects in lower-risk subjects is not quite as strong. Since sodium/glucose cotransporter-2 (SGLT-2) inhibitor treatment reduces CV events as well (with the effect mainly driven by a reduction in heart failure complications), the individual risk of ischemic or heart failure complications should guide the choice of treatment. GLP-1 RAs may also help prevent renal comp...

A Molecular Perspective on the Potential Benefits of Metformin for the Treatment of Inflammatory Skin Disorders

“…These results not only suggest a strong link between psoriasis and diabetes, but also suggest that the two diseases may share an inflammatory pathophysiology [34]. In terms of its association with diabetes, there is increasing evidence of the positive effects of anti-diabetic drugs on psoriasis including glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinedione and biguanide [35][36][37][38][39][40]. Therefore, it is important to summarize the clinical data that shows the anti-psoriatic effect of anti-hyperglycemic drugs and discuss their potential mechanisms of action.…”

Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials

“…Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a class of subcutaneous glucose-lowering drugs approved for the treatment of T2DM [22]. Large RCTs on GLP-1 RAs have also consistently demonstrated that these drugs exert beneficial effects on the risk of adverse cardiovascular outcomes, all-cause mortality and worsening of nephropathy in patients with T2DM [22][23][24]. GLP-1 RAs improve glycemic control while also reducing body weight and insulin resistance [22].…”

Therapies for the Treatment of Cardiovascular Disease Associated with Type 2 Diabetes and Dyslipidemia

“…It has a half-life of up to 2.4 h, 10 times longer than endogenous GLP1, because its resistance to human DPP4 degradation [ 81 , 82 ]. Since the first generated GLP1As have a subcutaneous administration twice daily, other compounds have been developed to extend durability [ 84 ]. The optimization approach was addressed to keep the human GLP1 backbone to avoid immunogenic problems [ 84 ] and to get DPP4 action resistance through GLP1-(7-36) region modifications [ 26 , 81 ].…”

“…Since the first generated GLP1As have a subcutaneous administration twice daily, other compounds have been developed to extend durability [ 84 ]. The optimization approach was addressed to keep the human GLP1 backbone to avoid immunogenic problems [ 84 ] and to get DPP4 action resistance through GLP1-(7-36) region modifications [ 26 , 81 ]. These modifications consist in the replacement of the penultimate alanine at the N-terminal end of the peptide by a glycine, serine, D-alanine, or by the most optimal chemical group, aminoisobutyric acid (Aib) [ 80 ], since it does not interfere with GLP1 receptor binding [ 85 ].…”

“…These compounds have shown favorable effects in experimental and clinical studies with the limitation of parenteral administration [ 26 , 82 ]. Therefore, current research is focused on developing novel small GLP1As to be administered orally [ 26 , 84 ]. Among these, oral semaglutide stands out, which is a small acetylated peptide [ 79 ] whose oral daily administration has recently been approved in combination with sodium N -(8-(2-hydroxybenzoyl) amino) caprylate (SNAC) [ 84 ].…”